Attention Deficit Hyperactivity Disorder Clinical Trials

Completed

Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder

NCT00419445

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit and Disruptive Behavior Disorders, +2 more
Locations: George Washington University Medical Center Washington D.C., District of Columbia, United States

Duke University Medical Center Durham, North Carolina, United States

View Trial Details

Completed

The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents

NCT00566371

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit and Disruptive Behavior Disorders, +8 more
Locations: Rhode Island Hospital Providence, Rhode Island, United States

View Trial Details

Completed

Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00546910

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit and Disruptive Behavior Disorders, +2 more
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Berlin, Germany

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Cologne, Germany

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Datteln, Germany

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Dorsten, Germany

View all 16 locations

View Trial Details

Completed

Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)

NCT00191906

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit and Disruptive Behavior Disorders, +13 more
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Ghent, Belgium

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Almere Stad, Netherlands

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Amsterdam, Netherlands

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Breda, Netherlands

View Trial Details

Completed

Efficacy and Effectiveness of Methylphenidate in Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder (ADHD)

NCT00482313

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit and Disruptive Behavior Disorders, +2 more
Locations: Stockholm County Council, Psychiatry Southwest Karolinska Huddinge, Stockholm County, Sweden

View Trial Details

Completed

Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD

NCT00029614

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit and Disruptive Behavior Disorders, +5 more
Locations: Western Psychiatric Institute and Clinic Pittsburgh, Pennsylvania, United States

View Trial Details

Completed

A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder

NCT00518232

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit and Disruptive Behavior Disorders, +2 more
Locations: Not specified

View Trial Details

Completed

A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents

NCT00447278

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit and Disruptive Behavior Disorders, +2 more
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Brussels, Belgium

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hoboken, Belgium

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leuven, Belgium

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Amiens, France

View all 35 locations

View Trial Details

Completed

A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00890292

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorder, +3 more
Locations: Not specified

View Trial Details

Completed

A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00890240

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorder, +3 more
Locations: Not specified

View Trial Details

Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder trial results

Related conditions